Browsing Tag
Zai Lab
9 posts
Is DLL3 becoming the most strategic biomarker target in neuroendocrine oncology?
Can dual DLL3 targeting improve SCLC outcomes? Read PDN’s deep analysis of the Boehringer Ingelheim and Zai Lab collaboration today.
Is this the most promising DLL3-targeting therapy yet? Zai Lab advances ADC into Phase 3
Zai Lab’s DLL3-targeting ADC for small cell lung cancer shows high brain metastasis activity; global Phase 3 trial now underway. Explore the data and future impact.
Innovent Biologics secures FDA greenlight for first global Phase 3 trial of IBI363 in lung cancer
Innovent Biologics wins FDA approval for its first global Phase 3 trial of IBI363 in lung cancer, signaling a major milestone in immuno-oncology.
U.S. stocks top gainers: Lyell Immunopharma, Applied Digital, and Guidewire surge amid investor optimism
Discover why Lyell Immunopharma, Applied Digital, and other top U.S. stocks surged on June 4, 2025. Comprehensive market analysis inside.
Zai Lab and Novocure’s TTFields therapy shows survival benefit in pancreatic cancer: PANOVA-3 results unveiled at ASCO 2025
Zai Lab and Novocure report TTFields improves survival in pancreatic cancer. Read how ASCO 2025 results could reshape the standard of care.
Biotech and Argentina-linked stocks lead April 11 US market rebound amid volatility and tariff headwinds
Discover why biotech, energy, and Argentina-linked stocks soared on April 11, 2025, as US markets rebounded despite global tariff tensions.
Zai Lab and Pfizer collaborate to address drug-resistant infections in China
Zai Lab and Pfizer have entered a partnership to commercialize XACDURO (sulbactam-durlobactam) in mainland China, addressing the rising…
Zai Lab treats first patient in China in PANOVA-3 trial of TTFields
Zai Lab Limited said that it has treated the first patient in Greater China in the PANOVA-3 phase…
Five Prime Therapeutics and Zai Lab start Phase 3 study of bemarituzumab for advanced gastric cancer
California-based Five Prime Therapeutics and Chinese biopharma Zai Lab have initiated a pivotal Phase 3 trial of bemarituzumab…